Serialization Update: Industry Warns Of “Significant Disruptions” If FDA Bars Use Of GSI Global Numbers Under DSCSA
Executive Summary
The pharmaceutical industry has already been using GTIN numbers on product packaging to comply with pending serialization requirements and US FDA’s plan to replace the GTIN with the NDC code is drawing much criticism.
You may also be interested in...
Pharmaceutical Groups Urge FDA To Upgrade From NDC To GTIN To Avoid Conflicts With DSCSA
Pharmaceutical manufacturers and distributors complain that FDA’s plan to add digits to the NDC would be a mistake and could potentially conflict with global standards as well as the bar code technology systems put into place under the Drug Supply Chain Security Act. They suggest embedding the NDC into the GS1 Global Trade Identification number (GTIN) to avoid these conflicts.
Industry Advised To ‘Lawyer Up’ If Serialization Systems Don’t Comply With DSCSA
Drug makers must comply with draft FDA guidance on Drug Supply Chain Security Act serialization requirements that took effect Nov. 27 or else “lawyer up” to explain to the agency why their products are not serialized in accordance with it, pharmaceutical lawyer advises.
Some Double Bar-Coding Required After November DSCSA Deadline, US FDA Says
As agency offers further guidance on how and when to begin complying with Drug Supply Chain Security Act requirements, one twist is that some packages will need two barcodes, depending on the circumstances.